What Is KPV? Mechanisms and Research on the α-MSH Tripeptide
In this article 9 sections
The short version: KPV is a tripeptide composed of lysine, proline, and valine. It corresponds to the C-terminal fragment of alpha-melanocyte-stimulating hormone (alpha-MSH), a neuropeptide that regulates inflammation and immune response. It is sold as a research-use-only laboratory chemical, not a medication. The published research on KPV is dominated by animal models and in-vitro studies, with limited human clinical trial data. Alta Peptides publishes lot-specific certificates of analysis for its research-grade KPV, which is the baseline standard any researcher should expect before ordering.
Search for “what is KPV” and you will find a range of explanations that either oversimplify the science or blur the line between the naturally occurring alpha-MSH fragment and the synthetic tripeptide sold as a research chemical. The two are related but not identical, and the distinction matters for understanding what the research literature actually supports.
This guide explains what KPV is, how it differs from the full alpha-MSH molecule, what the published research shows, and what documentation to verify before sourcing.
What KPV is, chemically
KPV is a tripeptide composed of lysine, proline, and valine. The sequence is Lys-Pro-Val. It corresponds to the C-terminal fragment of alpha-melanocyte-stimulating hormone, a neuropeptide that regulates inflammation, immune response, and pigmentation.
Alpha-MSH is a 13-amino-acid peptide derived from the pro-opiomelanocortin (POMC) precursor. The full molecule has a broad range of activities, including effects on pigmentation, appetite, and inflammation. KPV is a much shorter fragment that retains some of the anti-inflammatory activity of the parent molecule but is easier and cheaper to synthesise.
A study published in Gastroenterology in 2008 examined the anti-inflammatory effects of KPV in cell models and in two mouse models of colitis. The researchers found that KPV is taken up into intestinal epithelial and immune cells by the PepT1 peptide transporter, where nanomolar concentrations inhibited NF-kappaB and MAP kinase inflammatory signalling and reduced pro-inflammatory cytokine secretion. Oral KPV also reduced markers of colitis in the mice. The research was limited to cell and animal models.
A 2003 study in the Journal of Pharmacology and Experimental Therapeutics compared KPV with alpha-MSH and other melanocortin peptides in mouse models of peritonitis. KPV reduced inflammatory cell accumulation, but the authors concluded that its anti-inflammatory effect is clearly different from that of the core melanocortin peptides. None of this work involved human clinical trials.
The mechanism of action
Although KPV is derived from alpha-MSH, the published studies suggest it does not work mainly through melanocortin receptors. Instead, it appears to enter cells through the PepT1 transporter and dampen inflammatory signalling inside them.
Melanocortin receptor independence. The study published in 2003 found that KPV’s anti-inflammatory effect in mice was not blocked by a melanocortin 3/4 receptor antagonist, did not raise cAMP in macrophages, and persisted in mice lacking a functional MC1 receptor. The authors concluded that KPV is unlikely to act through melanocortin receptors and more likely works by inhibiting IL-1beta functions.
Cytokine modulation. KPV modulates the release of inflammatory cytokines, which are signalling molecules that regulate the immune response. The 2008 Gastroenterology study found that KPV, once taken up through PepT1, inhibited NF-kappaB and MAP kinase signalling and reduced pro-inflammatory cytokine secretion in cell models.
Delivery research. Because KPV is a small tripeptide, researchers have explored targeted delivery systems for it. A study published in 2010 loaded KPV into colon-targeted nanoparticles and reported similar effects in a mouse colitis model at a concentration about 12,000-fold lower than KPV in free solution.
What the research shows
The KPV literature is dominated by animal models and in-vitro studies. Human clinical trial data is limited, and no large randomised controlled trials have been published for any indication.
Inflammation research
The most studied application of KPV is in inflammation research. The compound is investigated for its effects on inflammatory cytokines and its ability to modulate the immune response. The 2008 Gastroenterology study found that oral KPV reduced markers of colitis, including pro-inflammatory cytokine expression, in two mouse models.
Mucosal healing research
KPV has been studied for its effects on mucosal healing in the gastrointestinal tract. The 2008 Gastroenterology study is one of the most cited works in this area, and it provides the basis for subsequent research into the compound’s effects on gut inflammation.
Immune modulation research
The compound is studied for its effects on immune cell function and cytokine release. The 2003 study found that KPV reduced inflammatory cell migration in mice but did not inhibit macrophage activation in vitro the way alpha-MSH did, suggesting a distinct mode of action.
Video: What is KPV used for?
This third-party video provides general context on KPV research. It is not affiliated with Alta Peptides and is not a substitute for laboratory documentation or the published literature.
How KPV compares to other research peptides
KPV is one of several peptides studied for anti-inflammatory or tissue-repair applications. Understanding how it compares to related compounds helps researchers choose the right tool for a given research question.
| Peptide | Origin | Primary research interest | Evidence level |
|---|---|---|---|
| KPV | Alpha-MSH fragment | Inflammation, immune modulation | Preclinical |
| BPC-157 | Gastric juice protein fragment | Angiogenesis, tissue repair | Preclinical |
| TB-500 | Thymosin beta-4 fragment | Cell migration, actin regulation | Preclinical |
| GHK-Cu | Copper-binding tripeptide | Collagen synthesis, matrix remodelling | Moderate for topical use |
The Alta Peptides overview of KPV summarises the research context and the documentation standards that apply.
The UK regulatory context
KPV is not a licensed medicine in the UK. It has not received a marketing authorisation from the MHRA. Research-grade KPV sold for laboratory use occupies a different regulatory space from licensed medicines. The research-use-only designation is a legal boundary that restricts the product to laboratory use.
The MHRA has been active in enforcing against illicit supply of unlicensed medicines. The agency’s record seizure announcement described the dismantling of a major weight loss medicine production facility, with thousands of doses seized.
For researchers, the practical implication is that a supplier’s compliance posture matters. A supplier that maintains a research-use-only boundary and publishes analytical documentation is operating within a recognised research supply channel.
The researcher’s verification checklist
1. Lot-specific certificate of analysis
A certificate of analysis (COA) is only meaningful if it corresponds to the exact lot you are buying. The COA should list the lot number, the testing laboratory, the report ID, the date the sample was received, and the date the results were published. The Alta Peptides KPV product page lists the current lot documentation alongside the price.
2. Complete analytical panel
A certificate that lists only “purity: 99%” is incomplete. The useful fields are identity by mass spectrometry, purity by HPLC, measured content, endotoxin, and sterility. If a supplier’s COA omits measured content or endotoxin, that is a gap.
3. Named independent laboratory
The testing laboratory should be identified and should be a different organisation from the supplier. In the UK, UKAS accreditation is the recognised mark of competence for testing laboratories.
4. Research-use-only boundary
The listing should not publish dosing, administration, or human-use content. A supplier that maintains the boundary consistently is easier to trust than one that publishes human-use content alongside the RUO label.
How Alta Peptides approaches KPV documentation
Alta Peptides is a UK-based research peptide supplier that publishes lot-specific documentation for each product configuration. The company’s certificates page collects the reports for all products. The recovery and repair category organises the compounds studied in this research area.
Comparing KPV with related compounds
| Feature | KPV | Full alpha-MSH |
|---|---|---|
| Length | 3 amino acids | 13 amino acids |
| Activity | Anti-inflammatory | Broad, including pigmentation |
| Synthesis cost | Lower | Higher |
| Regulatory status | Research-use-only | Not licensed |
Common questions about KPV
What is KPV?
KPV is a tripeptide composed of lysine, proline, and valine. It corresponds to the C-terminal fragment of alpha-melanocyte-stimulating hormone (alpha-MSH). It is sold as a research-use-only laboratory chemical.
How does KPV differ from alpha-MSH?
KPV is a three-amino-acid fragment of the full alpha-MSH molecule, which is 13 amino acids long. KPV retains some of the anti-inflammatory activity of the parent molecule but is smaller and easier to synthesise.
Has KPV been studied in human clinical trials?
Human clinical trial data for KPV is limited. The compound has been studied primarily in animal models and in-vitro systems. No large randomised controlled trials have been published for any indication.
What should a KPV COA show?
A complete COA should report identity by mass spectrometry, purity by HPLC with the method stated, measured content or assay value, endotoxin testing, and sterility testing. It should also include the lot number, the testing laboratory’s name, the report ID, and the dates of sample receipt and result reporting.
How do I verify that a KPV COA is real?
Check that the testing laboratory is named and that the report ID can be cross-referenced. Some laboratories publish verification portals where a report ID can be entered to confirm the document’s authenticity.
What should I do if a supplier’s listing makes health claims?
Treat it as a disqualifying signal. Health claims on a research peptide listing are the exact pattern that regulators have cited in enforcement actions.
Important notice: This article is provided for educational and informational purposes only. It does not constitute medical, legal, or regulatory advice. Research peptides discussed here are sold exclusively for laboratory research use and are not approved by the MHRA, the FDA, or any other regulatory agency for human or veterinary use. Nothing in this article should be construed as guidance for human consumption, dosing, or administration. Researchers are responsible for complying with all applicable laws and regulations in their jurisdiction. Always consult the product label, the certificate of analysis, and a qualified professional before making decisions about any substance.
Perry Reid
More articles by this author